nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
ono pharma,nordic group,otsuka,bms
['nivo', 'gastric', 'nivolumab', 'attraction-5']
addition of nivolumab to adjuvant chemo did not improve outcomes in resected gastric cancer, unselected for pdl-1 expression. attraction-5 trial. @
#asco23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded